report strong express deal near
ci report adj ep ahead opco/street
consensu adj result exclud amort transact
cost litig matter tax benefit beat larg
driven global healthcar gener segment incom opco
driven beat mcr ratio vs street
gov vs street rais ep guidanc
driven global healthcar
compani also reiter compound-annual-growth-rate ep result
rais ep estim
price target
recap global healthcar incom opco driven
opex ratio grew bp y-i partial hif line global
supp vs opco impact unfavor claim group
 solid vs opco
trend remain compani reduc industry-lead annual
cost trend project bp level metric
last year time compani note variou bucketsinpati
outpati pharmaci professionalar rang year
mid-single-digit target margin rang manag believ
could face after-tax declin book equal
bp return sustain margin manag expect
competit despit ad sixth statearizonait could see enrol
declin
headwinds/tailwind discuss besid impact individu
margin declin manag expect continu impact favor
meanwhil tailwind includ growth includ de-
leverag relat express script growth specialty/international/group
disabl also reiter target
conclus overal ci continu produc impress result
close express script expect year-end catalyst stori
remain promis valuat still remain depress result
maintain outperform rate would continu buyer stock
provid health care relat
benefit us intern
compani offer insur self-
health vision plan well
disabl life insur product
analyst certif import disclosur see disclosur
expos strong growth area healthcar also
avoid mani risk strong rel concentr
aso busi compani also strong track record
growth recent year tradit trade discount
peer although posit neg
express script deal believ compani balanc
sheet ripe take leverag highli accret deal
pay strong long-term return result rate stock
capit deploy contribut moder growth
guidanc issu updat
medicar busi growth margin acceler
signific uptick util
disabl life busi continu face volatil
exchang busi turn materi loss
price target base combin two methodolog dcf valuat base beta
termin growth rate wacc estim ebitda price-to-earnings target repres
ep estim conserv discount group current trade uncertainti around
express script sort
includ healthcar reform federal/st regul chang cost trend intern busi risk
premium fee
global care benefit expens
healthcar premium
health care benefit expens settlement
premium fee
total benefit expens
premium fee
oper expens revenu
pharmaci cost good sold
total benefit expens
incom attribut non-controlling interest
dilut ep report
premium fee
global care benefit expens
health care benefit expens settlement
total benefit expens
pharmaci cost good sold
total benefit expens
